| Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| VRX | NYSE | USD | Real-time | |
| VRX | NEO | CAD | Real-time | |
| VRX | Toronto | CAD | Delayed | |
| VRXN | Mexico | MXN | Delayed | |
| VRX | Switzerland | CHF | Delayed | |
| BVF | Stuttgart | EUR | Delayed | |
| BVF | Munich | EUR | Delayed | |
| BVF | Berlin | EUR | Delayed |
TG Therapeutics announces preliminary Phase 2 results. Geron’s imetelstat has positive Phase ⅔ clinical data. Agios Pharmaceuticals’s AG-348 moves to Phase 3.
NEW YORK, June 18 (Reuters) - * The Toronto Stock Exchange's S&P/TSX .GSPTSE rose 69.21 points, or 0.42 percent, to 16,383.63. * The biggest contributor to the TSX gain was...
The FDA has dealt the company some disappointing news on one of its late-stage drugs.
Stock markets in Europe, plus U.S. index futures are flat this morning, while currencies are steady. Commodities have been active, along with resource stocks. Overnight, both China...
Overnight surprises have had a significant impact on trading that could continue into today's action. President Trump surprised the world overnight by firing FBI Director Comey....
The Ides of March has arrived at last with the potential for significant market moving developments. U.S. indices and the FTSE are up 0.2% so far today. The U.S. dollar is...
| Type | 5 mins | 15 mins | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Buy | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Sell | Strong Sell | BUY |
| Summary | Strong Buy | Buy | Strong Sell | Neutral | Neutral |
Filter Table By:
| Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
|---|---|---|---|---|---|
| Emerging Patterns | |||||
| Doji Star Bearish | 15 | Current | |||
| Separating Lines Bullish | 30 | Current | |||
| Upside Gap Three Methods | 1W | Current | |||
| Engulfing Bearish | 1W | Current | |||
| Completed Patterns | |||||
| Three Outside Up | 1M | 1 | May 18 | ||
| Advance Block Bearish | 1D | 1 | Jun 21, 2018 | ||
| Bullish Engulfing | 1M | 2 | Apr 18 | ||
| Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| NYSE | 24.27 | 0.00 | 0.00 | 6,174,842 | -1.82% | USD | 22/06 | ||
| NEO | 32.22 | 0.00 | 0.00 | 18,255 | -2.04% | CAD | 22/06 | ||
| Toronto | 32.19 | 32.10 | 32.25 | 1,161,127 | -2.04% | CAD | 22/06 | ||
| Mexico | 487.00 | 0.00 | 0.00 | 5,172 | -2.99% | MXN | 22/06 | ||
| Switzerland | 24.600 | 0.000 | 0.000 | 0 | +0.00% | CHF | 21/06 | ||
| Stuttgart | 20.680 | 0.000 | 0.000 | 300 | -3.23% | EUR | 22/06 | ||
| Munich | 20.560 | 0.000 | 0.000 | 1,300 | -3.47% | EUR | 22/06 | ||
| Berlin | 21.220 | 0.000 | 0.000 | 0 | -0.38% | EUR | 22/06 |
| Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| Aurora Cannabis | 9.990 | 10.720 | 9.960 | -0.480 | -4.58% | 18.32M | 22/06 | ||
| Canopy Growth | 43.500 | 48.680 | 43.400 | -4.280 | -8.96% | 12.95M | 22/06 | ||
| Aphria | 12.710 | 13.450 | 12.260 | -0.400 | -3.05% | 11.00M | 22/06 | ||
| Green Organic Dutchman | 6.91 | 7.30 | 6.90 | -0.14 | -1.99% | 1.12M | 22/06 | ||
| Auxly Cannabis | 1.2700 | 1.4500 | 1.2700 | -0.0600 | -4.51% | 5.19M | 22/06 | ||
| iQIYI | 36.29 | 39.80 | 35.11 | -2.54 | -6.54% | 52.78M | 22/06 | ||
| Tesla | 333.63 | 352.25 | 332.00 | -13.88 | -3.99% | 10.27M | 22/06 | ||
| Hydropothecary | 5.3000 | 5.3700 | 5.0000 | +0.0000 | +0.00% | 0 | 21/06 | ||
| Amazon.com | 1,715.67 | 1,743.00 | 1,711.90 | -14.55 | -0.84% | 4.08M | 22/06 | ||
| Netflix | 411.09 | 420.50 | 409.65 | -4.35 | -1.05% | 10.43M | 22/06 |
Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.
Read More
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
